266 related articles for article (PubMed ID: 16977790)
1. [Cyclooxygenase inhibitors: a never ending story?].
Macrì R; Manfredi C
G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
[No Abstract] [Full Text] [Related]
2. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
3. Coxibs and cardiovascular disease.
Fitzgerald GA
N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
[No Abstract] [Full Text] [Related]
4. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
5. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
6. Differences between COX-2-specific inhibitors: clinical and economic implications.
Sonnenblick EH
Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
[No Abstract] [Full Text] [Related]
7. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
8. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Jugdutt BI
Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
[No Abstract] [Full Text] [Related]
9. [Cyclooxygenase-2 inhibitors and the ethics of research].
Gherardi CR
Medicina (B Aires); 2005; 65(5):476. PubMed ID: 16296649
[No Abstract] [Full Text] [Related]
10. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
11. Rofecoxib, Merck, and the FDA.
Wolfe MM
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
[No Abstract] [Full Text] [Related]
12. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
13. Does the dose make the poison?
Harris RE
Science; 2005 Apr; 308(5719):203. PubMed ID: 15821073
[No Abstract] [Full Text] [Related]
14. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Vanchieri C
J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
[No Abstract] [Full Text] [Related]
15. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
16. Cox-2 inhibitors: still no decisive action.
Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
[TBL] [Abstract][Full Text] [Related]
17. Institutional review boards must conduct safety review.
Maloney DM
Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
[No Abstract] [Full Text] [Related]
18. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
19. COX-2 inhibitors: cancer prevention or cardiovascular risk?
Senior K
Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289
[No Abstract] [Full Text] [Related]
20. COX-2 selective inhibitors--important lessons learned.
Maxwell SR; Webb DJ
Lancet; 2005 Feb 5-11; 365(9458):449-51. PubMed ID: 15705439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
